Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + LDRT in locally advanced dMMR/MSI-H gastric cancer
NCT06426654Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by West China Hospital of Sichuan University. Primary endpoints: Optimal radiation dose for phase II study and Pathological Complete Response Rate. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06426654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06426654.